Abstract
While pharmaceutical prices have always differed across countries, rising drug costs in the United States have increased interest in the potential for arbitrage and moved the issue to center stage. At first blush, parallel trade in pharmaceuticals appears to be the solution to rising drug prices. However, a more nuanced consideration of the issue reveals it to be more complicated and less straightforward. This paper examines the economic incentives involved in pharmaceutical reimportation with a particular focus on the risks of counterfeit pharmaceuticals and the role of patent protection in continued research and development. The public policy ramifications and quality implications are also considered. Reimportation is a complicated issue that has the potential to shape both health care policy and the look of the pharmaceutical industry.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Pharmaceutical Marketing & Management
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
